Voyager Therapeutics PE Ratio 2014-2022 | VYGR

Current and historical p/e ratio for Voyager Therapeutics (VYGR) from 2014 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Voyager Therapeutics PE ratio as of May 27, 2022 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Voyager Therapeutics PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-05-27 6.05 0.00
2022-03-31 7.62 $-1.88 0.00
2021-12-31 2.71 $-1.90 0.00
2021-09-30 2.63 $-2.48 0.00
2021-06-30 4.13 $0.46 8.98
2021-03-31 4.71 $1.03 4.57
2020-12-31 7.15 $0.95 7.53
2020-09-30 10.67 $1.04 10.26
2020-06-30 12.62 $-1.64 0.00
2020-03-31 9.15 $-1.12 0.00
2019-12-31 13.95 $-1.27 0.00
2019-09-30 17.21 $-1.63 0.00
2019-06-30 27.22 $-1.85 0.00
2019-03-31 19.14 $-2.94 0.00
2018-12-31 9.40 $-2.76 0.00
2018-09-30 18.92 $-2.46 0.00
2018-06-30 19.54 $-2.72 0.00
2018-03-31 18.79 $-2.65 0.00
2017-12-31 16.60 $-2.67 0.00
2017-09-30 20.59 $-2.84 0.00
2017-06-30 8.96 $-2.30 0.00
2017-03-31 13.24 $-1.94 0.00
2016-12-31 12.74 $-1.58 0.00
2016-09-30 12.01 $-1.68 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.233B $0.037B
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00